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amplified the variable 3′ end of the B646L (p72) gene by using 
2 oligonucleotide primers, p72-U and p72-D (3). To amplify 
the entire E183L gene (p54), we used primers described by 
Oviedo et al. (8), and to amplify the tetramer amino acid re-
peats within the hypervariable central variable region of the 
B602L gene, we used primers described by Gallardo et al. 
(5). Our results showed that sequences for all ASFV isolates 
from this outbreak and those for isolates previously collected 
in eastern Europe and eastern Africa were 100% homologous 
over the p72, p54, and central variable region gene-coding re-
gions. The p72 sequences clustered in genotype II (Figure).
During the 2015 ASFV outbreak in Zimbabwe, a total of 
3,427 pigs were at risk for infection in the affected area. Of 
those, 2,836 (≈83%) became infected, and all infected pigs 
died. The 591 pigs that did not become infected had been 
confined in pens and did not have exposure to infected pigs 
or their products. A follow-up study is under way in the re-
gion to genetically characterize the viruses in this outbreak, 
focusing on the p54, p30 and, central variable region genes.
All villages affected during the 2015 outbreak in Zim-
babwe were along the northern border with Mozambique, 
where genotype II has been found before. It is essential that 
more of the ASFVs circulating in eastern and southern Afri-
ca be sequenced so that their relatedness can be determined. 
This knowledge will enable the establishment of an epidemi-
ologic link between outbreaks in the region and underscore 
the need for adequate quarantine measures to prevent ASF 
from becoming endemic in southern and eastern Africa.
Dr. van Heerden is a senior researcher in the Transboundary 
Animal Diseases Program at the Agricultural Research Council–
Onderstepoort Veterinary Institute. Her research work mainly 
focuses on molecular characterization and epidemiology of 
African swine fever.
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Two cases of Bartonella prosthetic valve endocarditis were 
cured when treated for 2 weeks with gentamicin and 3 
months with doxycycline. Clinical cure correlated with de-
creased Bartonella antibody titers. This report suggests a 
strategy to monitor, treat, and cure Bartonella prosthetic 
valve endocarditis.
Bartonella, a causative agent of blood culture–negative endocarditis (BCNE) that usually requires valve sur-
gery, was first attributed to endocarditis over 20 years ago 
(1–4). We report 2 cases of Bartonella prosthetic valve en-
docarditis that were successfully treated with antimicrobial 
drugs alone.
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Case 1 involved a 62-year-old man admitted to the 
hospital in 2011 with left-flank pain and a 3-year history 
of anorexia, weight loss, night sweats, and recent diagno-
sis of anemia. He kept pet cats. He underwent mechanical 
aortic valve replacement and patent foramen ovale closure 
in 1992 and a repeat aortic valve replacement and an aortic 
root replacement for a chronic type A dissection in 1996. 
On physical examination, he was afebrile and had sub-
conjunctival hemorrhages, normal prosthetic heart sounds, 
and 10-cm splenomegaly. Blood tests showed a hemoglobin 
concentration of 9 g/dL (reference range 14.0–17.5 g/dL), 
serum creatinine of 2.76 mg/dL (reference range 0.6–1.2 
mg/dL), C-reactive protein of 48 mg/L (reference range 
0.08–3.1 mg/L), rheumatoid factor of 742 U/mL (reference 
range 0–30 U/mL), and c-ANCA (cytoplasmic antineutrophil 
cytoplasmic antibody) positivity (proteinase 3 autoantibody 
concentration, 18.3 U/mL). Urine dipstick (Combur 7 Test; 
Roche Diagnostics Ltd, Basel, Switzerland) revealed the 
presence of blood (4+), and renal biopsy demonstrated nec-
rotizing crescentic glomerulonephritis. Five blood cultures 
were sterile. Transesophageal echocardiography showed no 
evidence of endocarditis. Bartonella serologic testing was 
conducted with an indirect immunofluorescence assay by 
using the manufacturer’s instructions (MRL, Cypress, CA, 
USA); results showed high IgG titers to both B. henselae and 
B. quintana (Table), but the infecting species could not be 
determined. The patient was treated for 2 weeks with intra-
venous gentamicin (2 mg/kg/d) and for 3 months with oral 
doxycycline (100 mg 2×/d). Nine months after completing 
treatment, he was well: splenomegaly had resolved, and he-
moglobin (15.6 g/dL) and creatinine (1.31 mg/dL) concen-
trations approached normal levels. He was well when last 
reviewed in 2014.
Case 2 involved a 29-year-old woman with inflamma-
tory bowel disease and primary sclerosing cholangitis. Her 
symptoms began in 2011 with fever, rigors, night sweats, 
and anorexia for 2 weeks. She had no pets but recalled 
contact with a kitten 8 months previously. In 2002, BCNE 
developed, requiring mechanical aortic and mitral valve 
replacements. In 2003, BCNE was again diagnosed but 
was complicated by an ascending aorta to left atrial fistula, 
requiring an aortic root replacement, a homograft, and a 
repeat mechanical mitral valve replacement. 
Physical examination revealed fever, a splinter hem-
orrhage, and an ejection systolic murmur. Blood tests re-
vealed a low hemoglobin concentration (10.9 g/dL), a high 
C-reactive protein concentration (26 mg/L), normal renal 
function, and positivity for rheumatoid factor (114 U/mL). 
Transesophageal echocardiograms revealed no evidence of 
endocarditis. One of 20 blood culture tests grew B. hense-
lae after a 19-day incubation (Public Health England, iden-
tified by partial sequencing of 16S rDNA). A serologic test 
for Bartonella was strongly positive (Table). Three days af-
ter starting treatment with oral doxycycline (100 mg 2×/d) 
and intravenous gentamicin (3 mg/kg/d), she became afe-
brile; she received 14 days of gentamicin and 3 months of 
doxycycline in total. Two months later, she remained well, 
and her C-reactive protein concentration was <5 mg/L. 
Because of symptomatic stenosis caused by structural de-
terioration of the replacement aortic valve, she underwent 
another aortic valve and root replacement 19 months after 
completing antimicrobial drugs. No evidence of active en-
docarditis was found during surgery. 
Bartonella antibody titers dropped slowly over a peri-
od of 3 years in both patients (Table). Only case 1 had defi-
nite infective endocarditis when using the modified Duke 
diagnostic criteria. However, because the Duke criteria are 
insensitive for BCNE diagnosis, it has been proposed that 
a Bartonella IgG titer of >1:800 and a positive Western 
blot or PCR analysis when using valve or blood specimens 
should be considered major Duke criteria (5). 
Most reported cases of Bartonella endocarditis involve 
native valves; the first prosthetic valve infection was report-
ed in 2002 (6). Although >80% of patients require valve re-
placement, infection with Bartonella is not in itself a recog-
nized indication for surgery. Because our patients responded 
to medication, we did not need to consider cardiac surgery. 
The optimal antimicrobial drug therapy and duration for 
Bartonella endocarditis is undetermined. The recommended 
regimen of gentamicin for 14 days and doxycycline for 4 
weeks (7) has limited evidence supporting its use (8,9). We 
found only 1 case of Bartonella prosthetic valve endocarditis 





Table. Bartonella antibody titers in cases 1 and 2 by month after diagnosis* 
Month after diagnosis B. henselae IgM B. henselae IgG B. quintana IgM B. quintana IgG 
Case 1 
 0 40 32,768 <20 1,024 
 8 <20 16,385 <20 512 
 11 20 8,096 <20 512 
 16 <20 8,096 <20 256 
 25 <20 4,096 <20 64 
 43 <20 2,048 <20 64 
Case 2 
 0 <20 8,192 <20 512 
 16 <20 ≥512 <20 64 
 41 <20 64 <20 <64 
*All time points were assayed in parallel. Antibody titers are the inverse of the greatest dilution that exhibited a reaction. 
 
 
cured without valve surgery; it was cured with a 30-month 
antimicrobial drug regimen (10). 
The role for serial serologic testing in assessing cure 
of Bartonella endocarditis is unknown. In our cases, as in 
a previous report (10), a drop in Bartonella titers occurred 
over a 3-year period in those who were cured, suggesting 
follow-up serologic testing might be useful to assess Bar-
tonella endocarditis clinical cure.
Our findings suggest that a simple, inexpensive drug 
regimen is optimal therapy for Bartonella endocarditis and 
that serial serologic testing can confirm adequate treatment 
and cure. Further research is needed to validate this ap-
proach to managing Bartonella endocarditis.
Dr. Papineni is a Specialist Registrar in Infectious Diseases and 
General Medicine in the London Deanery. She is currently a 
clinical research fellow at the National University of Singapore 
with a research interest in shortening treatment of tuberculosis.
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We tested whole-blood and plasma samples from immuno-
competent patients who had had benign Zika virus infec-
tions and found that Zika virus RNA persisted in whole blood 
substantially longer than in plasma. This finding may have 
implications for diagnosis of acute symptomatic and asymp-
tomatic infections and for testing of blood donations.
Since cases of severe neurologic disorders among adults (1) and fetal abnormalities (2) linked to Zika virus 
infections were initially reported, the World Health Or-
ganization has deemed the Zika virus outbreak a “public 
health emergency of international concern” and has raised 
Zika virus to the same level of concern as Ebola virus. In 
response, medical authorities from many countries have 
released advice and guidelines regarding prevention and 
diagnosis to contain the spread of this virus and guidelines 
regarding safety of whole blood and blood components. 
In August 2016, the Food and Drug Administration an-
nounced universal testing for Zika virus RNA in donated 
whole blood and blood components taken in the United 
States and its territories using a qualitative molecular assay 
on plasma specimens (3).
In Europe, advice on Zika virus regarding the safety of 
substances of human origin (4) has been applied in France 
since February 15, 2016. A qualitative individual molecu-
lar test for Zika virus RNA in plasma specimens is being 
used on whole-blood specimens from blood donors living 
in Guadeloupe and Martinique, 2 overseas administrative 
areas where Zika virus is autochthonous. Furthermore, in 
mainland France and in French overseas areas where no 
active Zika virus transmission exists, and since the begin-
ning of the Zika virus outbreak in 2015, blood donors who 
have recently visited areas or countries with ongoing Zika 
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